PHILADELPHIA, PA — Vittoria Biotherapeutics Inc. has announced its upcoming presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois. The trials-in-progress poster will spotlight the design and goals of the ongoing Phase 1 study of VIPER-101, the company’s lead investigational CD5-targeted CAR-T therapy for relapsed or refractory T-cell lymphoma.
The presentation will take place on Sunday, June 1, 2025, at 9:00 a.m. CT in Hall A (Poster Board #268a). It represents the first clinical application of Vittoria’s proprietary Senza5™ platform, an advanced CAR-T engineering and manufacturing system designed to enhance the potency, durability, and safety of cell therapies.
The open-label Phase 1 trial aims to evaluate the safety and preliminary efficacy of VIPER-101 and determine the recommended Phase 2 dose (RP2D) in patients with relapsed or refractory CD5-positive T-cell non-Hodgkin lymphoma (NHL). The study leverages the Senza5 platform’s capability to genetically modify CAR T cells by disabling the CD5-mediated pathway, amplifying the cells’ antitumor activity.
VIPER-101 is a dual-population, gene-edited cell therapy specifically designed to target CD5, which is expressed in over 85% of T-cell lymphoma cases. Preclinical studies have demonstrated significant efficacy advantages of VIPER-101 compared to traditional CD5-targeted CAR-T approaches.
Highlighting the objectives of Senza5, the platform employs a proprietary five-day manufacturing process, designed to maximize therapeutic durability and stemness. By bypassing CD5’s immunosuppressive effects, the expedited process enhances the therapy’s in vivo expansion and response potential.
“This Phase 1 study is a significant milestone for Vittoria Biotherapeutics, marking the clinical debut of our Senza5 platform and its groundbreaking potential for T-cell lymphoma patients,” the company noted.
The trial is actively recruiting patients, and Vittoria Biotherapeutics showcases confidence in the innovative solution’s ability to address critical gaps in lymphoma treatment and improve patient outcomes.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.